These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21514823)

  • 21. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
    Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
    J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents.
    Kim ND; Park ES; Kim YH; Moon SK; Lee SS; Ahn SK; Yu DY; No KT; Kim KH
    Bioorg Med Chem; 2010 Oct; 18(19):7092-100. PubMed ID: 20810285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity.
    El Turk F; Fauvet B; Ouertatani-Sakouhi H; Lugari A; Betzi S; Roche P; Morelli X; Lashuel HA
    Bioorg Med Chem; 2010 Jul; 18(14):5425-40. PubMed ID: 20639113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory potential of chemical substitutions at bioinspired sites of β-D-galactopyranose on neoglycoprotein/cell surface binding of two classes of medically relevant lectins.
    Giguère D; André S; Bonin MA; Bellefleur MA; Provencal A; Cloutier P; Pucci B; Roy R; Gabius HJ
    Bioorg Med Chem; 2011 May; 19(10):3280-7. PubMed ID: 21524586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioactivity-guided navigation of chemical space.
    Bon RS; Waldmann H
    Acc Chem Res; 2010 Aug; 43(8):1103-14. PubMed ID: 20481515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinatorial approach toward synthesis of small molecule libraries as bacterial transglycosylase inhibitors.
    Shih HW; Chen KT; Chen SK; Huang CY; Cheng TJ; Ma C; Wong CH; Cheng WC
    Org Biomol Chem; 2010 Jun; 8(11):2586-93. PubMed ID: 20485795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical informatics: using molecular shape descriptors in structure-based drug design.
    Jennings A
    Methods Mol Biol; 2012; 841():235-50. PubMed ID: 22222455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
    da Silva VB; Taft CA; Silva CH
    J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and identification of a new class of triarylmethyl amine compounds as inhibitors of apolipoprotein E production.
    Singh M; Schott JT; Leon MA; Granata RT; Dhah HK; Welles JA; Boyce MA; Oseni-Olalemi HS; Mordaunt CE; Vargas AJ; Patel NV; Maitra S
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6252-5. PubMed ID: 22959206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of small molecule inhibitors of human COQ7.
    Tsuganezawa K; Sekimata K; Nakagawa Y; Utata R; Nakamura K; Ogawa N; Koyama H; Shirouzu M; Fukami T; Kita K; Tanaka A
    Bioorg Med Chem; 2020 Jan; 28(1):115182. PubMed ID: 31753803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
    Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G
    J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of N-phenylacetyl (sulfonyl) 4,5-dihydropyrazole derivatives as potential antitumor agents.
    Liu XH; Ruan BF; Liu JX; Song BA; Jing LH; Li J; Yang Y; Zhu HL; Qi XB
    Bioorg Med Chem Lett; 2011 May; 21(10):2916-20. PubMed ID: 21486698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles.
    Li CM; Lu Y; Narayanan R; Miller DD; Dalton JT
    Drug Metab Dispos; 2010 Nov; 38(11):2032-9. PubMed ID: 20675405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.
    Zhu Z; Sun ZY; Ye Y; Voigt J; Strickland C; Smith EM; Cumming J; Wang L; Wong J; Wang YS; Wyss DF; Chen X; Kuvelkar R; Kennedy ME; Favreau L; Parker E; McKittrick BA; Stamford A; Czarniecki M; Greenlee W; Hunter JC
    J Med Chem; 2010 Feb; 53(3):951-65. PubMed ID: 20043696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of screening libraries based on the muurolane natural product scaffold.
    Barnes EC; Choomuenwai V; Andrews KT; Quinn RJ; Davis RA
    Org Biomol Chem; 2012 May; 10(20):4015-23. PubMed ID: 22422350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
    Radi M; Crespan E; Botta G; Falchi F; Maga G; Manetti F; Corradi V; Mancini M; Santucci MA; Schenone S; Botta M
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1207-11. PubMed ID: 18078752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electron density guided fragment-based drug design--a lead generation example.
    Abad MC; Gibbs AC; Zhang X
    Methods Enzymol; 2011; 493():487-508. PubMed ID: 21371603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward the comprehensive systematic enumeration and synthesis of novel kinase inhibitors based on a 4-anilinoquinazoline binding mode.
    Kettle JG; Ward RA
    J Chem Inf Model; 2010 Apr; 50(4):525-33. PubMed ID: 20141221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
    Wang YS; Strickland C; Voigt JH; Kennedy ME; Beyer BM; Senior MM; Smith EM; Nechuta TL; Madison VS; Czarniecki M; McKittrick BA; Stamford AW; Parker EM; Hunter JC; Greenlee WJ; Wyss DF
    J Med Chem; 2010 Feb; 53(3):942-50. PubMed ID: 20043700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic.
    Al-Abed Y; VanPatten S
    Future Med Chem; 2011 Jan; 3(1):45-63. PubMed ID: 21428825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.